Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?

Ellen M. Cahill; John L. Pfail; Melinda Z. Fu; Biren Saraiya; Tina Mayer; Ryan D. Stephenson; Ronald D. Ennis; Lara Hathout; Matthew P. Deek; Saum Ghodoussipour; Thomas L. Jang

doi:10.1007/s11934-023-01159-4

Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?

Ellen M. Cahill, John L. Pfail, Melinda Z. Fu, Biren Saraiya, Tina Mayer, Ryan D. Stephenson, Ronald D. Ennis, Lara Hathout, Matthew P. Deek, Saum Ghodoussipour, Thomas L. Jang

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Purpose of Review: The standard treatment of patients with metastatic prostate cancer is systemic treatment with androgen-deprivation therapy (ADT). The spectrum-based model of metastatic disease includes the presence of an oligometastatic state, an intermediary between localized and widespread metastatic disease, in which radical local treatment might improve systemic control. Our purpose is to review the literature on metastasis-directed therapy in the treatment of oligometastatic prostate cancer. Recent Findings: Several prospective clinical trials have reported improvements in ADT-free survival and progression-free survival with metastasis-directed therapy of oligometastatic prostate cancer. Summary: Retrospective studies have found improvements in oncologic outcomes for patients with oligometastatic prostate cancer undergoing metastasis-directed therapy, and several recent prospective clinical trials have confirmed these results. Advancements in imaging as well as an understanding of the genomics of oligometastatic prostate cancer may allow for better patient selection for metastasis-directed therapy and the potential for cure in selected patients.

Original language	English (US)
Pages (from-to)	299-306
Number of pages	8
Journal	Current urology reports
Volume	24
Issue number	7
DOIs	https://doi.org/10.1007/s11934-023-01159-4
State	Published - Jul 2023

All Science Journal Classification (ASJC) codes

Urology

Keywords

Metastasis-directed therapy
Oligometastatic prostate cancer
Prostate cancer
Stereotactic body radiation therapy

Access to Document

10.1007/s11934-023-01159-4

Cite this

@article{85e749cd699e4b3bb0c2bc00c9aefa71,

title = "Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?",

abstract = "Purpose of Review: The standard treatment of patients with metastatic prostate cancer is systemic treatment with androgen-deprivation therapy (ADT). The spectrum-based model of metastatic disease includes the presence of an oligometastatic state, an intermediary between localized and widespread metastatic disease, in which radical local treatment might improve systemic control. Our purpose is to review the literature on metastasis-directed therapy in the treatment of oligometastatic prostate cancer. Recent Findings: Several prospective clinical trials have reported improvements in ADT-free survival and progression-free survival with metastasis-directed therapy of oligometastatic prostate cancer. Summary: Retrospective studies have found improvements in oncologic outcomes for patients with oligometastatic prostate cancer undergoing metastasis-directed therapy, and several recent prospective clinical trials have confirmed these results. Advancements in imaging as well as an understanding of the genomics of oligometastatic prostate cancer may allow for better patient selection for metastasis-directed therapy and the potential for cure in selected patients.",

keywords = "Metastasis-directed therapy, Oligometastatic prostate cancer, Prostate cancer, Stereotactic body radiation therapy",

author = "Cahill, {Ellen M.} and Pfail, {John L.} and Fu, {Melinda Z.} and Biren Saraiya and Tina Mayer and Stephenson, {Ryan D.} and Ennis, {Ronald D.} and Lara Hathout and Deek, {Matthew P.} and Saum Ghodoussipour and Jang, {Thomas L.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2023",

month = jul,

doi = "10.1007/s11934-023-01159-4",

language = "English (US)",

volume = "24",

pages = "299--306",

journal = "Current urology reports",

issn = "1527-2737",

publisher = "Current Science, Inc.",

number = "7",

}

TY - JOUR

T1 - Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer

T2 - An Alternative to ADT?

AU - Cahill, Ellen M.

AU - Pfail, John L.

AU - Fu, Melinda Z.

AU - Saraiya, Biren

AU - Mayer, Tina

AU - Stephenson, Ryan D.

AU - Ennis, Ronald D.

AU - Hathout, Lara

AU - Deek, Matthew P.

AU - Ghodoussipour, Saum

AU - Jang, Thomas L.

PY - 2023/7

Y1 - 2023/7

N2 - Purpose of Review: The standard treatment of patients with metastatic prostate cancer is systemic treatment with androgen-deprivation therapy (ADT). The spectrum-based model of metastatic disease includes the presence of an oligometastatic state, an intermediary between localized and widespread metastatic disease, in which radical local treatment might improve systemic control. Our purpose is to review the literature on metastasis-directed therapy in the treatment of oligometastatic prostate cancer. Recent Findings: Several prospective clinical trials have reported improvements in ADT-free survival and progression-free survival with metastasis-directed therapy of oligometastatic prostate cancer. Summary: Retrospective studies have found improvements in oncologic outcomes for patients with oligometastatic prostate cancer undergoing metastasis-directed therapy, and several recent prospective clinical trials have confirmed these results. Advancements in imaging as well as an understanding of the genomics of oligometastatic prostate cancer may allow for better patient selection for metastasis-directed therapy and the potential for cure in selected patients.

AB - Purpose of Review: The standard treatment of patients with metastatic prostate cancer is systemic treatment with androgen-deprivation therapy (ADT). The spectrum-based model of metastatic disease includes the presence of an oligometastatic state, an intermediary between localized and widespread metastatic disease, in which radical local treatment might improve systemic control. Our purpose is to review the literature on metastasis-directed therapy in the treatment of oligometastatic prostate cancer. Recent Findings: Several prospective clinical trials have reported improvements in ADT-free survival and progression-free survival with metastasis-directed therapy of oligometastatic prostate cancer. Summary: Retrospective studies have found improvements in oncologic outcomes for patients with oligometastatic prostate cancer undergoing metastasis-directed therapy, and several recent prospective clinical trials have confirmed these results. Advancements in imaging as well as an understanding of the genomics of oligometastatic prostate cancer may allow for better patient selection for metastasis-directed therapy and the potential for cure in selected patients.

KW - Metastasis-directed therapy

KW - Oligometastatic prostate cancer

KW - Prostate cancer

KW - Stereotactic body radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85151557038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151557038&partnerID=8YFLogxK

U2 - 10.1007/s11934-023-01159-4

DO - 10.1007/s11934-023-01159-4

M3 - Review article

C2 - 37017928

AN - SCOPUS:85151557038

SN - 1527-2737

VL - 24

SP - 299

EP - 306

JO - Current urology reports

JF - Current urology reports

IS - 7

ER -

Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this